MDM2 and neoplasm: The tumor-promoting function of CRY1 has been further suggested in a recent study showing that CRY1 enhances p53 tumor suppressor degradation via p53 binding to its ubiquitin E3 ligase MDM2 proto‐oncogene in bladder cancer cells, thereby increasing anticancer drug sensitivity50.